Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Hims & Hers: Personalized Care To Sustain Revenue Growth Despite GLP-1 Hiccup
11:51am, Friday, 22'nd Aug 2025
I remain bullish on Hims & Hers Health due to its resilient subscriber growth and strong positioning in the expanding personalized care and telehealth markets. Despite the loss of the GLP-1 contract w
Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions
07:32am, Wednesday, 20'th Aug 2025
jetcityimage / iStock Editorial via Getty Images Eli Lilly stock was up more than 50% in 2024, before declining in 2025.
GLP-1 drug Wegovy approved to treat liver disease, what's driving Q2 earnings results
01:47pm, Monday, 18'th Aug 2025
Morning Brief anchor Julie Hyman breaks down the latest market news for August 18, 2025. Novo Nordisk's weight loss drug Wegovy is the first GLP-1 drug approved to treat liver disease.
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead
09:00am, Saturday, 16'th Aug 2025
The ongoing compounding/ regulatory headwinds have triggered LLY's and NVO's painful corrections, worsened by the notable market rotation to AI boom. LLY's double beat FQ2'25 performance, raised FY202
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
09:20am, Thursday, 14'th Aug 2025
Kelowna, British Columbia – TheNewswire - August 14, 2025 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platform
Global Partners (GLP) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Tuesday, 12'th Aug 2025
Global Partners (GLP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should Value Investors Buy Global Partners (GLP) Stock?
10:40am, Tuesday, 12'th Aug 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Best Value Stocks to Buy for August 12th
06:40am, Tuesday, 12'th Aug 2025
ESEA, GLP and HRTG made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 12, 2025.
Global Partners (GLP) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Monday, 11'th Aug 2025
Global Partners (GLP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
10:00am, Saturday, 09'th Aug 2025
This week, drugmakers had a scare when President Trump threatened to levy tariffs of up to 250% on imported pharmaceuticals. The news jolted the health care sector, which fell by 2.74% over the past f
Global Partners LP Common Units (GLP) Q2 2025 Earnings Call Transcript
01:15pm, Thursday, 07'th Aug 2025
Global Partners LP Common Units (NYSE:GLP ) Q2 2025 Earnings Conference Call August 7, 2025 10:00 AM ET Company Participants Eric S. Slifka - President, CEO & Vice Chairman of Global GP LLC Gregory B.
Global Partners (GLP) Q2 EPS Falls 50%
11:09am, Thursday, 07'th Aug 2025
Global Partners (GLP) Q2 EPS Falls 50%
Hims & Hers: A High-Risk Bet
10:27am, Thursday, 07'th Aug 2025
Upgrading Hims & Hers Health, Inc. to a speculative Buy after a 20% post-earnings selloff, given management's reaffirmed guidance and near-term demand for personalized compounded GLP-1s. I believe the
Global Partners Reports Second-Quarter 2025 Financial Results
08:00am, Thursday, 07'th Aug 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) today reported financial results for the second quarter ended June 30, 2025. CEO Commentary “F
In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved th
